688185 Stock Overview
Develops, manufactures, and commercializes vaccines in the People’s Republic of China. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
CanSino Biologics Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$64.50 |
| 52 Week High | HK$87.50 |
| 52 Week Low | HK$37.12 |
| Beta | 0.49 |
| 11 Month Change | 12.43% |
| 3 Month Change | 65.22% |
| 1 Year Change | -22.29% |
| 33 Year Change | -75.98% |
| 5 Year Change | n/a |
| Change since IPO | -83.59% |
Recent News & Updates
Recent updates
Shareholder Returns
| 688185 | CN Biotechs | CN Market | |
|---|---|---|---|
| 7D | -4.6% | -1.9% | -2.8% |
| 1Y | -22.3% | -21.0% | 2.0% |
Return vs Industry: 688185 underperformed the CN Biotechs industry which returned -21% over the past year.
Return vs Market: 688185 underperformed the CN Market which returned 2% over the past year.
Price Volatility
| 688185 volatility | |
|---|---|
| 688185 Average Weekly Movement | 12.2% |
| Biotechs Industry Average Movement | 9.0% |
| Market Average Movement | 8.4% |
| 10% most volatile stocks in CN Market | 12.7% |
| 10% least volatile stocks in CN Market | 5.6% |
Stable Share Price: 688185's share price has been volatile over the past 3 months compared to the CN market.
Volatility Over Time: 688185's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of CN stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 1,149 | Xuefeng Yu | www.cansinotech.com |
CanSino Biologics Inc. develops, manufactures, and commercializes vaccines in the People’s Republic of China. The company develops Convidecia and the Ad5-nCoV for Inhalation vaccines to recombinant novel coronavirus disease; Ad5-EBOV, an Ebola virus vaccine; and MCV2 and MCV4 vaccines for the prevention of N. meningitides. It develops DTcP vaccine for infants and DTcP Booster vaccine, which are in Phase I clinical trial for addressing the weaker protection preventing pertussis after primary vaccination.
CanSino Biologics Inc. Fundamentals Summary
| 688185 fundamental statistics | |
|---|---|
| Market cap | CN¥10.66b |
| Earnings (TTM) | -CN¥720.11m |
| Revenue (TTM) | CN¥748.53m |
8.3x
P/S Ratio-8.7x
P/E RatioIs 688185 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 688185 income statement (TTM) | |
|---|---|
| Revenue | CN¥748.53m |
| Cost of Revenue | CN¥774.40m |
| Gross Profit | -CN¥25.87m |
| Other Expenses | CN¥694.25m |
| Earnings | -CN¥720.11m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.91 |
| Gross Margin | -3.46% |
| Net Profit Margin | -96.20% |
| Debt/Equity Ratio | 41.3% |
How did 688185 perform over the long term?
See historical performance and comparison